Insider activity (SEC Form 4)
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
Open-market · last 30 days:
0 buyers bought $0
1 seller sold $406K
Open-market · last 90 days:
0 buyers bought $0
3 sellers sold $46.6M
| Insider | Role | Date | Transaction | Shares | Value |
| Moreland Mary K |
EXECUTIVE VICE PRESIDENT |
2026-11-05 |
Open-market sell |
3500 |
$406K |
| Conroy Kevin T |
Director |
2026-09-23 |
Tax withholding |
52507 |
$5.5M |
| MCCOY JOHN A. JR. |
VICE PRESIDENT AND CONTROLLER |
2026-09-02 |
Open-market sell |
27 |
$3K |
| Boudreau Philip P |
EVP AND CFO |
2026-09-01 |
Tax withholding |
388 |
$43K |
| MCCOY JOHN A. JR. |
VICE PRESIDENT AND CONTROLLER |
2026-09-01 |
Tax withholding |
52 |
$6K |
| Ford Robert B |
CHAIRMAN AND CEO, Director |
2026-08-25 |
Option exercise |
151869 |
$6.7M |
| Ford Robert B |
CHAIRMAN AND CEO, Director |
2026-08-25 |
Option exercise |
246963 |
$14.8M |
| Ford Robert B |
CHAIRMAN AND CEO, Director |
2026-08-25 |
Open-market sell |
218535 |
$25.3M |
| Ford Robert B |
CHAIRMAN AND CEO, Director |
2026-08-25 |
Open-market sell |
180297 |
$20.9M |
| Morrone Louis H. |
EXECUTIVE VICE PRESIDENT |
2026-08-12 |
I |
12 |
$1K |
| Morrone Louis H. |
EXECUTIVE VICE PRESIDENT |
2026-08-11 |
Open-market sell |
5850 |
$643K |
| Morrone Louis H. |
EXECUTIVE VICE PRESIDENT |
2026-06-30 |
Tax withholding |
269 |
$25K |
| Cushman Elizabeth C. |
EVP, GC AND SECRETARY |
2026-06-27 |
Tax withholding |
560 |
$53K |
| Stratton John G |
Director |
2026-05-07 |
Open-market buy |
2000 |
$174K |
| Moreland Mary K |
EXECUTIVE VICE PRESIDENT |
2026-04-28 |
I |
5314 |
$502K |
| STARKS DANIEL J |
Director |
2026-04-27 |
Open-market buy |
10000 |
$927K |
| Ahuja Nita |
Director |
2026-04-24 |
Grant/award |
2286 |
$0 |
| Babineaux-Fontenot Claire |
Director |
2026-04-24 |
Grant/award |
2286 |
$0 |
| Blount Sally E. |
Director |
2026-04-24 |
Grant/award |
2286 |
$0 |
| Conroy Kevin T |
Director |
2026-04-24 |
Grant/award |
2286 |
$0 |
Most recent 20 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.
8-K
filed 2026-10-21
confidence 95%
Item 8.01
Abbott announced its intention to separate its global Nutrition business into an independent, publicly traded company through a tax-free distribution to shareholders, expected to be completed by end of 2027. This constitutes a material disposition and change of control event—the Nutrition business with ~$8.5 billion in annual sales will be spun off as a separate entity, fundamentally restructuring Abbott's portfolio and creating two distinct public companies. The announcement explicitly states this is a separation transaction with regulatory approvals and Board approval required, fitting the definition of material M&A activity under Items 1.01/2.01.
View raw filing on EDGAR →
8-K
filed 2026-10-21
confidence 98%
Item 2.02
Abbott announced third-quarter 2026 financial results on October 21, 2026, disclosing net sales of $13.013 billion (14.5% reported growth, 7.0% comparable growth), GAAP diluted EPS of $0.53, and adjusted diluted EPS of $1.42. The news release, furnished as Exhibit 99.1, presents comprehensive quarterly results across all business segments (Nutrition, Diagnostics, Established Pharmaceuticals, Medical Devices) and reaffirms full-year 2026 adjusted EPS guidance. This is a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →
8-K
filed 2026-08-20
confidence 95%
Item 8.01
Abbott announced settlement of material litigation involving specialty formulas for preterm infants, resolving the Gill case (which had a $495 million jury verdict in July 2024) and claims on behalf of approximately 2,000 other individuals for an aggregate settlement amount of approximately $670 million, with approximately 1,700 pending lawsuits involving approximately 12,700 individual infants remaining.
View raw filing on EDGAR →
8-K
filed 2026-07-16
confidence 98%
Item 2.02
Abbott disclosed its second-quarter 2026 financial results on July 16, 2026, including reported sales growth of 13.0%, comparable sales growth of 4.8%, GAAP diluted EPS of $0.53, and adjusted diluted EPS of $1.31. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45–$5.60. This is a standard quarterly earnings release furnished as Exhibit 99.1, filed under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →